Management Team

Our management team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to pharmaceutical development, BD deals and corporate finance. This combination of skill sets enables the team to effectively execute our business plan.

DHS photo.jpeg

Dr. David Horn Solomon

Chief Executive Officer

RQ photo2.jpg

Dr. Rob Quinn

Chief Financial Officer

GC photo.jpg

Dr. Giles Campion

Head of R&D and Chief Medical Officer

JS photo 2.jpg

Dr. John Strafford

VP, Head of Business Development

LE photo 4.jpg

Linnea Elrington

VP, Head of Human Resources

Dr. David Horn Solomon

Chief Executive Officer

David is an experienced public company biotech CEO, board member and biotech investor. He was the CEO of Zealand Pharma A/S (NASDAQ:ZEAL) from 2008 to 2015. Under David’s leadership the company went public on NASDAQ OMX and its lead product, Adlixin®, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved in the US and globally and is now marketed by Sanofi as a monotherapy and in combination with Lantus as Soliqua®. David was also the CEO of Bionor Pharma ASA (OSL:BIONOR) and Akari Therapeutics, Plc (NASDAQ:AKTX), and was the Managing Partner of Sund Capital, ApS, a Nordic healthcare investment fund.

He has earlier served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York City. From 2003 to 2006, David headed healthcare investment at Carrot Capital Healthcare Ventures in New York. David is currently a member of the Board of Directors of TxCell SA (NYSE EURONEXT:TXCL), and was earlier a member of the Boards at Onxeo SA (NYSE EURONEXT:ONXEO) and Promosome, LLC. Dr Solomon studied at Weil Cornell Medicine of Cornell University and its Graduate School of Medical Science where he received his Ph.D.

DHS photo.jpeg

Appointed

July 2018

Areas of expertise

Biotech corporate finance, pharmaceutical development, business development agreements, biotech governance

Current external roles

Director of TxCell SA

Dr. Rob Quinn

Chief Financial Officer

Rob was appointed as Chief Financial Officer and Company Secretary of Silence in January 2019. Rob holds a PhD in Biochemistry from the University of Manchester and is a qualified chartered accountant.

Following his PhD Rob trained as an accountant at Deloitte before joining GlaxoSmithKline (2013-2017), with time spent working in internal audit, M&A and commercial finance. Rob’s last role at GSK was as Area Finance Director for the Africa & Developing Countries business unit, covering sales of pharmaceuticals and vaccines to over 45 countries. Rob joined Silence in April 2017 as Head of Financial Planning and Analysis before broadening his responsibilities to Legal, IT and Manufacturing.

RQ photo2.jpg

Appointed

January 2019

Dr. Giles Campion

Head of R&D and Chief Medical Officer

Giles is an expert in translational medicine, and a highly experienced biotech and pharmaceutical professional across all therapeutic areas, most recently in orphan neuromuscular disorders. He has held senior global R&D roles in large pharmaceutical, diagnostics, and biotech companies, including responsibility at Board level. He served as Chief Medical Officer and Senior Vice-President of R&D at Prosensa from 2009 to 2016, during which time the company signed a collaborative agreement with GSK worth up to $680 million with double digit royalties on product sales and co-commercialisation rights in certain territories. Prosensa went on to list on NASDAQ in 2013, raising $89.7 million in an offering nine times oversubscribed, and was eventually acquired by Biomarin in 2015 for $680 million.

Most recently, he served as Chief Medical Officer for Albumedix , Advisor to Myotherix, and a co-founder of PepGen, all companies focusing on therapies for rare diseases. At Albumedix his remit was to build a development portfolio based on the company’s recombinant albumin platform and his work was instrumental in product development and an eventual financial exit for the owners of the company.

Giles holds a medical degree and doctorate from Bristol University and is Board certified in Rheumatology.

GC photo.jpg

Appointed

June 2019

Dr. John Strafford

VP, Head of Business Development

John was appointed Vice President, Head of Business Development for Silence in May 2019. He has broad experience in biotech, management consulting, and specialty pharma, and has a track record in identifying strategic business opportunities and delivering significant commercial value for biotech growth. At Concordia International, a global specialty pharmaceutical company with over $600m in revenues, he was responsible for the end-to-end business development process and played a key role in the development of robust portfolio management processes, accelerating the identification of new product opportunities and driving pipeline value growth.

John earned his PhD in Biochemical Engineering at University College London and his BSc in Molecular Biology from the University of Edinburgh. He received the Pharma Licensing Group (PLG) Business Development Best Newcomer of the Year Award in 2009 and is the author of several scientific publications.

JS photo 2.jpg

Appointed

May 2019

Linnea Elrington

VP, Head of Human Resources

Linnea is an experienced international HR professional and has delivered high impact People programs across many cultures in PE-backed, start-up and global expansion projects. She was the Global Head of Organisation Development at Glory Global Solutions where she oversaw post-acquisition cultural integration programs as well as the development and implementation of executive, management, and employee development and training programs, succession planning, talent management, performance management systems, and organizational effectiveness initiatives. She earlier served in several senior HR roles at Deloitte in North America, Central and Eastern Europe, and Russia.

Linnea is a Chartered member of the Institute for Personnel and Development. She earned an MSc in Social and Organisational Psychology from the London School of Economics and a BA in History from Wesleyan University in the USA.

LE photo 4.jpg

Appointed

November 2017